Skip to main navigation
Skip to search
Skip to main content
The Capital Region of Denmark's Research Portal Home
Dansk
English
Search content at The Capital Region of Denmark's Research Portal
Home
Hospitals/departments
Researchers
Research output
Activities
Prizes
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran
EXTEND Study Group
Department of Orthopaedic Surgery
74
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Safety Assessment
100%
Antithrombotic Agents
100%
Ximelagatran
100%
Enoxaparin
27%
Liver Toxicity
27%
Prolonged Administration
18%
Relative Efficacy
9%
Treatment Withdrawal
9%
Venous Thromboembolism Prevention
9%
Study Termination
9%
Alanine Aminotransferase
9%
Postoperative Day
9%
Premature Termination
9%
Clinical Development
9%
Liver Injury
9%
Oral Direct Thrombin Inhibitor
9%
Hip Replacement
9%
Liver Enzymes
9%
Days of Treatment
9%
Hip Fracture Surgery
9%
Upper Normal Limit
9%
Pharmacology, Toxicology and Pharmaceutical Science
Anticoagulant Agent
100%
Ximelagatran
100%
Safety Assessment
100%
Enoxaparin
27%
Hepatotoxicity
27%
Symptom
9%
Venous Thromboembolism
9%
Prematurity
9%
Hip Fracture
9%
Liver Injury
9%
Thrombin Inhibitor
9%
Liver Enzyme
9%
Alanine Aminotransferase
9%